147 related articles for article (PubMed ID: 23661230)
1. Chiral ruthenium(II) complexes with phenolic hydroxyl groups as dual poisons of topoisomerases I and IIα.
Zhang P; Wang J; Huang H; Qiao L; Ji L; Chao H
Dalton Trans; 2013 Jun; 42(24):8907-17. PubMed ID: 23661230
[TBL] [Abstract][Full Text] [Related]
2. Dual topoisomerase I and II poisoning by chiral Ru(II) complexes containing 2-thiophenylimidazo[4,5-f][1,10]phenanthroline derivatives.
Wang YC; Qian C; Peng ZL; Hou XJ; Wang LL; Chao H; Ji LN
J Inorg Biochem; 2014 Jan; 130():15-27. PubMed ID: 24145066
[TBL] [Abstract][Full Text] [Related]
3. Chiral ruthenium(II) anthraquinone complexes as dual inhibitors of topoisomerases I and II.
Kou JF; Qian C; Wang JQ; Chen X; Wang LL; Chao H; Ji LN
J Biol Inorg Chem; 2012 Jan; 17(1):81-96. PubMed ID: 21858685
[TBL] [Abstract][Full Text] [Related]
4. Dual inhibition of topoisomerases I and IIα by ruthenium(II) complexes containing asymmetric tridentate ligands.
Du K; Liang J; Wang Y; Kou J; Qian C; Ji L; Chao H
Dalton Trans; 2014 Dec; 43(46):17303-16. PubMed ID: 25315107
[TBL] [Abstract][Full Text] [Related]
5. Ruthenium(II) polypyridyl complexes with 1,8-naphthalimide group as DNA binder, photonuclease, and dual inhibitors of topoisomerases I and IIα.
Sun Y; Li J; Zhao H; Tan L
J Inorg Biochem; 2016 Oct; 163():88-94. PubMed ID: 27470011
[TBL] [Abstract][Full Text] [Related]
6. Topoisomerase IIα poisoning and DNA double-strand breaking by chiral ruthenium(ii) complexes containing 2-furanyl-imidazo[4,5-f][1,10]phenanthroline derivatives.
Qian C; Wu J; Ji L; Chao H
Dalton Trans; 2016 Jun; 45(26):10546-55. PubMed ID: 27226117
[TBL] [Abstract][Full Text] [Related]
7. Design, synthesis and systematic evaluation of cytotoxic 3-heteroarylisoquinolinamines as topoisomerases inhibitors.
My Van HT; Woo H; Jeong HM; Khadka DB; Yang SH; Zhao C; Jin Y; Lee ES; Youl Lee K; Kwon Y; Cho WJ
Eur J Med Chem; 2014 Jul; 82():181-94. PubMed ID: 24904965
[TBL] [Abstract][Full Text] [Related]
8. 4β-[4'-(1-(Aryl)ureido)benzamide]podophyllotoxins as DNA topoisomerase I and IIα inhibitors and apoptosis inducing agents.
Kamal A; Suresh P; Ramaiah MJ; Srinivasa Reddy T; Kapavarapu RK; Rao BN; Imthiajali S; Lakshminarayan Reddy T; Pushpavalli SN; Shankaraiah N; Pal-Bhadra M
Bioorg Med Chem; 2013 Sep; 21(17):5198-208. PubMed ID: 23849207
[TBL] [Abstract][Full Text] [Related]
9. The role of cell cycle regulation and apoptosis triggering in determining the sensitivity of leukemic cells to topoisomerase I and II inhibitors.
Dubrez L; Goldwasser F; Genne P; Pommier Y; Solary E
Leukemia; 1995 Jun; 9(6):1013-24. PubMed ID: 7596166
[TBL] [Abstract][Full Text] [Related]
10. Synthesis, topoisomerase I and II inhibitory activity, cytotoxicity, and structure-activity relationship study of 2-phenyl- or hydroxylated 2-phenyl-4-aryl-5H-indeno[1,2-b]pyridines.
Kadayat TM; Song C; Shin S; Magar TB; Bist G; Shrestha A; Thapa P; Na Y; Kwon Y; Lee ES
Bioorg Med Chem; 2015 Jul; 23(13):3499-512. PubMed ID: 26022080
[TBL] [Abstract][Full Text] [Related]
11. Synthesis and biological evaluation of benzo[a]phenazine derivatives as a dual inhibitor of topoisomerase I and II.
Zhuo ST; Li CY; Hu MH; Chen SB; Yao PF; Huang SL; Ou TM; Tan JH; An LK; Li D; Gu LQ; Huang ZS
Org Biomol Chem; 2013 Jun; 11(24):3989-4005. PubMed ID: 23657605
[TBL] [Abstract][Full Text] [Related]
12. [Poisons of DNA topoisomerases I and II].
Charcosset JY; Soues S; Laval F
Bull Cancer; 1993 Nov; 80(11):923-54. PubMed ID: 8081034
[TBL] [Abstract][Full Text] [Related]
13. Differential cytotoxic pathways of topoisomerase I and II anticancer agents after overexpression of the E2F-1/DP-1 transcription factor complex.
Hofland K; Petersen BO; Falck J; Helin K; Jensen PB; Sehested M
Clin Cancer Res; 2000 Apr; 6(4):1488-97. PubMed ID: 10778981
[TBL] [Abstract][Full Text] [Related]
14. Synthesis and evaluation of novel ellipticines as potential anti-cancer agents.
Deane FM; O'Sullivan EC; Maguire AR; Gilbert J; Sakoff JA; McCluskey A; McCarthy FO
Org Biomol Chem; 2013 Feb; 11(8):1334-44. PubMed ID: 23314103
[TBL] [Abstract][Full Text] [Related]
15. Evodiamine, a dual catalytic inhibitor of type I and II topoisomerases, exhibits enhanced inhibition against camptothecin resistant cells.
Pan X; Hartley JM; Hartley JA; White KN; Wang Z; Bligh SW
Phytomedicine; 2012 May; 19(7):618-24. PubMed ID: 22402246
[TBL] [Abstract][Full Text] [Related]
16. Cyclometalated platinum(II) complexes as topoisomerase IIα poisons.
Liu J; Leung CH; Chow AL; Sun RW; Yan SC; Che CM
Chem Commun (Camb); 2011 Jan; 47(2):719-21. PubMed ID: 21072335
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of DNA topoisomerases I and II and growth inhibition of HL-60 cells by novel acridine-based compounds.
Janočková J; Plšíková J; Kašpárková J; Brabec V; Jendželovský R; Mikeš J; Kovaľ J; Hamuľaková S; Fedoročko P; Kuča K; Kožurková M
Eur J Pharm Sci; 2015 Aug; 76():192-202. PubMed ID: 25960253
[TBL] [Abstract][Full Text] [Related]
18. Design, synthesis and biological evaluation of novel 7-alkylamino substituted benzo[a]phenazin derivatives as dual topoisomerase I/II inhibitors.
Yao BL; Mai YW; Chen SB; Xie HT; Yao PF; Ou TM; Tan JH; Wang HG; Li D; Huang SL; Gu LQ; Huang ZS
Eur J Med Chem; 2015 Mar; 92():540-53. PubMed ID: 25599951
[TBL] [Abstract][Full Text] [Related]
19. Topotecan-induced topoisomerase IIalpha expression increases the sensitivity of the CML cell line K562 to subsequent etoposide plus mitoxantrone treatment.
Chen S; Gomez SP; McCarley D; Mainwaring MG
Cancer Chemother Pharmacol; 2002 May; 49(5):347-55. PubMed ID: 11976828
[TBL] [Abstract][Full Text] [Related]
20. Effect of cellular ATP depletion on topoisomerase II poisons. Abrogation Of cleavable-complex formation by etoposide but not by amsacrine.
Sorensen M; Sehested M; Jensen PB
Mol Pharmacol; 1999 Mar; 55(3):424-31. PubMed ID: 10051525
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]